-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M2AI1NLgFnmcJpujE7Ed7I96FHmhymBalBpNV6ESR0xTsbelTEE0zFSwm+LT75px pGFnz0o3v2XTXhtgP7sTNg== 0000950149-07-000023.txt : 20070212 0000950149-07-000023.hdr.sgml : 20070212 20070212133724 ACCESSION NUMBER: 0000950149-07-000023 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070212 DATE AS OF CHANGE: 20070212 GROUP MEMBERS: ANSBERT GADICKE GROUP MEMBERS: LUKE EVNIN GROUP MEMBERS: MPM ASSET MANAGEMENT INVESTORS 1998 LLC GROUP MEMBERS: MPM BIO VENTURES PARALLEL FUND LP FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOVENTURES L P CENTRAL INDEX KEY: 0001040662 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 62 DE RUYTURES CITY: CURACAO NETHERLANDS ANTILLES STATE: P8 MAIL ADDRESS: STREET 1: 111 HUNTINGTON AVE 31ST FL CITY: BOSTON STATE: MA ZIP: 02119 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IDENIX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001093649 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450478605 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79969 FILM NUMBER: 07601692 BUSINESS ADDRESS: STREET 1: 60 HAMPSHIRE STREET STREET 2: . CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 250-3100 MAIL ADDRESS: STREET 1: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: NOVIRIO PHARMACEUTICALS LTD DATE OF NAME CHANGE: 19990820 SC 13G/A 1 f27249sc13gza.htm AMENDMENT TO SCHEDULE 13G sc13gza
 

     
 
OMB APPROVAL
  
 
OMB Number: 3235-0145
  
 
Expires: February 28, 2009
  
 
Estimated average burden hours per response...10.4
  
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

IDENIX PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
45166R 20 4
(CUSIP Number)
December 31, 2006
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     o Rule 13d-1(c)

     þ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

                     
CUSIP No.
  
45166R 20 4 
  

 

           
1   NAMES OF REPORTING PERSONS:
BB BioVentures L.P.
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   2,949,488
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   2,949,488
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  2,949,488
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  5.3%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 2 of 11

 

                     
CUSIP No.
  
45166R 20 4 
  

 

           
1   NAMES OF REPORTING PERSONS:
MPM BioVentures Parallel Fund, L.P.
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   256,519
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   256,519
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  256,519
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.5%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN

Page 3 of 11

 

                     
CUSIP No.
  
45166R 20 4 
  

 

           
1   NAMES OF REPORTING PERSONS:
MPM Asset Management Investors 1998 LLC
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   37,299
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   37,299
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  37,299
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  0.1%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  OO

Page 4 of 11

 

                     
CUSIP No.
  
45166R 20 4 
  

 

           
1   NAMES OF REPORTING PERSONS:
Ansbert Gadicke
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   0
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   3,243,306*
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   0
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    3,243,306*
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  3,243,306*
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  5.78%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
*The shares are held as follows: 2,949,488 by BB BioVentures L.P. (“BB BioVentures”), 256,519 by MPM BioVentures Parallel Fund, L.P. (“MPM Parallel”) and 37,299 by MPM Asset Management Investors 1998 LLC (“MPM Investors”). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (“BAB BV”), BAB BioVentures NV and MPM BioVentures I LLC (“BioVentures LLC”) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (“BioVentures LP”) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of MPM Investors and BioVentures LLC.

Page 5 of 11

 

                     
CUSIP No.
  
45166R 20 4 
  

 

           
1   NAMES OF REPORTING PERSONS:
Luke Evnin
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
   
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   þ
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   0
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   3,243,306*
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   0
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    3,243,306*
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  3,243,306*
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  5.78%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
*The shares are held as follows: 2,949,488 by BB BioVentures L.P. (“BB BioVentures”), 256,519 by MPM BioVentures Parallel Fund, L.P. (“MPM Parallel”) and 37,299 by MPM Asset Management Investors 1998 LLC (“MPM Investors”). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (“BAB BV”), BAB BioVentures NV and MPM BioVentures I LLC (“BioVentures LLC”) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (“BioVentures LP”) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of MPM Investors and BioVentures LLC.

Page 6 of 11

 

Item 1.
  (a)   Name of Issuer
Idenix Pharmaceuticals, Inc.
 
  (b)   Address of Issuer’s Principal Executive Offices
60 Hampshire Street
Boston, MA 02139
Item 2.
  (a)   Name of Person Filing
BB BioVentures, LP
MPM BioVentures Parallel Fund, LP
MPM Asset Management Investors 1998 LLC
Ansbert Gadicke
Luke Evnin
  (b)   Address of Principal Business Office or, if none, Residence
c/o MPM Capital L.P.
The John Hancock Tower
200 Clarendon Street, 54th Floor
Boston, MA 02116
  (c)   Citizenship
               All entities were organized in Delaware and all individuals are United States citizens.
  (d)   Title of Class of Securities
               Common Stock
  (e)   CUSIP Number
               45166R 20 4
Item 3.  If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
                    Not applicable
Item 4. Ownership
  (a)   Amount Beneficially Owned:
         
BB BioVentures, LP
     2,949,488  
MPM BioVentures Parallel Fund, LP
     256,519  
MPM Asset Management Investors 1998 LLC
     37,299  
Ansbert Gadicke
     3,243,306 *
Luke Evnin
     3,243,306 *
Page 7 of 11

 

 

(b)   Percent of Class:
         
BB BioVentures, LP
     5.3 %
MPM BioVentures Parallel Fund, LP
     0.5 %
MPM Asset Management Investors 1998 LLC
     0.1 %
Ansbert Gadicke
     5.78 %
Luke Evnin
     5.78 %
(c)   Number of shares as to which the person has:
  (i)   Sole power to vote or to direct the vote
         
BB BioVentures, LP
     2,949,488  
MPM BioVentures Parallel Fund, LP
     256,519  
MPM Asset Management Investors 1998 LLC
     37,299  
Ansbert Gadicke
     0  
Luke Evnin
     0  
  (ii)   Shared power to vote or to direct the vote
         
BB BioVentures, LP
     0  
MPM BioVentures Parallel Fund, LP
     0  
MPM Asset Management Investors 1998 LLC
    0  
Ansbert Gadicke
     3,243,306 *
Luke Evnin
     3,243,306 *
  (iii)   Sole power to dispose or to direct the disposition of
         
BB BioVentures, LP
     2,949,488  
MPM BioVentures Parallel Fund, LP
     256,519  
MPM Asset Management Investors 1998 LLC
     37,299  
Ansbert Gadicke
     0  
Luke Evnin
     0  

Page 8 of 11

 

  (iv)   Shared power to dispose or to direct the disposition of
         
BB BioVentures, LP
     0  
MPM BioVentures Parallel Fund, LP
     0  
MPM Asset Management Investors 1998 LLC
     0  
Ansbert Gadicke
     3,243,306 **
Luke Evnin
     3,243,306 **
*The shares are held as follows: 2,949,488 by BB BioVentures L.P. (“BB BioVentures”), 256,519 by MPM BioVentures Parallel Fund, L.P. (“MPM Parallel”) and 37,299 by MPM Asset Management Investors 1998 LLC (“MPM Investors”). BB BioVentures is under common control with MPM Parallel and MPM Investors. BAB BioVentures L.P. (“BAB BV”), BAB BioVentures NV and MPM BioVentures I LLC (“BioVentures LLC”) are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P. (“BioVentures LP”) and BioVentures LLC are the direct and indirect general partners of MPM Parallel. The Reporting person is a manager of MPM Investors and BioVentures LLC.
Item 5.   Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
Item 6.   Ownership of More than Five Percent on Behalf of Another Person
          Not Applicable
Item 7.   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
          Not Applicable
Item 8.   Identification and Classification of Members of the Group
          Not Applicable
Item 9.   Notice of Dissolution of a Group
          Not Applicable
Item 10.   Certification
          Not Applicable
Page 9 of 11

 

 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 9, 2007
                 
BB BIOVENTURES L.P.   MPM BIOVENTURES PARALLEL FUND, L.P.    
 
                
By:
  BAB BioVentures L.P.,   By:   MPM BioVentures I LP,    
 
  its General Partner       its General Partner    
 
                
By:
  BAB BioVentures N.V.,   By:   MPM BioVentures I LLC,    
 
  its General Partner       its General Partner    
 
                
By:
     /s/ Ansbert Gadicke   By:      /s/ Luke Evnin    
 
 
 
Name: Ansbert Gadicke 		     
 
Name: Luke B. Evnin 		   
 
  Title: Managing Director       Title: Manager    
 
                
MPM ASSET MANAGEMENT INVESTORS
1998 LLC		            
 
                
By:
     /s/ Luke Evnin   By:     /s/ Ansbert Gadicke    
 
 
 
Name: Luke B. Evnin 		     
 
Name: Ansbert Gadicke 		   
 
  Title: Manager            
 
                
By:
     /s/ Luke Evnin            
 
 
 
Name: Luke B. Evnin 		           
Page 10 of 11

 

 

EXHIBIT A
JOINT FILING AGREEMENT
     In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Idenix Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
     In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 9th day of February, 2007.
                 
BB BIOVENTURES L.P.   MPM BIOVENTURES PARALLEL FUND, L.P.    
 
                
By:
  BAB BioVentures L.P.,   By:   MPM BioVentures I LP,    
 
  its General Partner       its General Partner    
 
                
By:
  BAB BioVentures N.V.,   By:   MPM BioVentures I LLC,    
 
  its General Partner       its General Partner    
 
                
By:
    /s/ Ansbert Gadicke   By:     /s/ Luke Evnin    
 
 
 
Name: Ansbert Gadicke 		     
 
Name: Luke B. Evnin 		   
 
  Title: Managing Director       Title: Manager    
 
                
MPM ASSET MANAGEMENT INVESTORS
1998 LLC		            
 
                
By:
    /s/ Luke Evnin   By:     /s/ Ansbert Gadicke    
 
 
 
Name: Luke B. Evnin 		     
 
Name: Ansbert Gadicke 		   
 
  Title: Manager            
 
                
By:
     /s/ Luke Evnin
 
Name: Luke B. Evnin 		           
Page 11 of 11

 

-----END PRIVACY-ENHANCED MESSAGE-----